Inventiva’s Lanifibranor On NASH Path After Phase II Success In NAFLD Patients With Diabetes

But All Eyes On NASH

 
• By Ayisha Sharma
  
Generate a summary of this article
Listen to this article
Beta

The French biotech’s PPAR agonist has significantly reduced liver fat in non-alcoholic fatty liver patients with type 2 diabetes in a mid-stage trial, raising hopes for success in an ongoing pivotal program in non-alcoholic steatohepatitis.  

tree pruned into shape of liver
The NASH Market Could Br Worth $26bn In Future • Source: Shutterstock

Key Takeaways:

  • Lanifibranor is a first-in-class pan PPAR agonist for the treatment of fatty liver diseases.

Inventiva S.A.’s lead candidate, lanifibranor, has shown promise in a Phase II trial of non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes, boding well for an ongoing Phase III trial in a more advanced form of the condition.

Lanifibranor works by activating all three isoforms of the peroxisome proliferator‑activated receptor (PPAR). It is the only pan-PPAR agonist in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D